Open Access<p>Acquisition of T790M resistance mutation in a patient with advanced adenocarcinoma harboring uncommon <em>EGFR</em> mutations: a case report and literature review</p>
Author(s) -
Taiki Hakozaki,
Makiko Yomota
Publication year - 2019
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s190034
Subject(s) - t790m , osimertinib , mutation , medicine , acquired resistance , lung cancer , adenocarcinoma , resistance mutation , cancer research , tyrosine kinase inhibitor , oncology , cancer , gene , biology , genetics , polymerase chain reaction , ros1 , reverse transcriptase
Osimertinib is the standard of care for patients with non-small-cell lung cancer (NSCLC) patients harboring acquired EGFR T790M resistance mutation. However, the frequency of T790M resistance mutation acquisition and the efficacy of osimertinib in patients harboring uncommon EGFR mutations, which accounts for approximately 10% of EGFR mutations, remain unclear.